Raw results: numbers of patients achieving the efficacy criteria ACR20, ACR50, and ACR70.
| Responding Patients | ||||||
|---|---|---|---|---|---|---|
| Active Treatment | Study | Treatment | No. Patients Included | ACR20, n (%) | ACR50, n (%) | ACR70, n (%) |
| Infliximab | Maini21 | Placebo | 88 | 18 (20) | 4 (5) | 0 (0) |
| Infliximab | 86 | 43 (50) | 22 (26) | 7 (8) | ||
| Schiff22 | Placebo | 110 | 46 (42) | 22 (20) | 10 (9) | |
| Infliximab | 165 | 98 (59) | 61 (37) | 40 (24) | ||
| Westhovens23 | Placebo | 363 | 87 (25) | 33 (10) | 16 (5) | |
| Infliximab | 360 | 199 (58) | 110 (32) | 48 (14) | ||
| Zhang24 | Placebo | 86 | 42 (49) | 22 (26) | 12 (14) | |
| Infliximab | 87 | 66 (76) | 38 (44) | 20 (23) | ||
| Etanercept | Weinblatt25 | Placebo | 30 | 8 (27) | 1 (3) | 0 (0) |
| Etanercept | 59 | 42 (71) | 23 (39) | 9 (15) | ||
| Combe26 | Placebo | 50 | 14 (28) | 7 (14) | 1 (2) | |
| Etanercept | 101 | 75 (74) | 53 (52) | 25 (25) | ||
| Adalimumab | Weinblatt27 | Placebo | 62 | 9 (15) | 5 (8) | 3 (5) |
| Adalimumab | 67 | 45 (67) | 37 (55) | 18 (27) | ||
| Keystone28 | Placebo | 200 | 59 (30) | 19 (10) | 5 (3) | |
| Adalimumab | 207 | 131 (63) | 81 (39) | 43 (21) | ||
| Kim29 | Placebo | 63 | 23 (37) | 9 (14) | 5 (8) | |
| Adalimumab | 65 | 40 (62) | 28 (43) | 14 (22) | ||
| Furst30 | Placebo | 318 | 111 (35) | 36 (11) | 11 (4) | |
| Adalimumab | 318 | 168 (53) | 92 (29) | 48 (15) | ||
| Golimumab | Keystone31 | Placebo | 133 | 37 (28) | 18 (14) | 7 (5) |
| Golimumab | 89 | 53 (60) | 33 (37) | 18 (20) | ||
| Kay32 | Placebo | 35 | 13 (37) | 2 (6) | 0 (0) | |
| Golimumab | 35 | 21 (60) | 13 (37) | 3 (9) | ||
| Certolizumab pegol | Keystone5 | Placebo | 199 | 27 (14) | 15 (8) | 6 (3) |
| Certolizumab pegol | 393 | 231 (59) | 146 (37) | 84 (21) | ||
| Smolen6 | Placebo | 127 | 11 (9) | 4 (3) | 1 (1) | |
| Certolizumab pegol | 246 | 141 (57) | 80 (33) | 39 (16) | ||
| Anakinra | Cohen33 | Placebo | 251 | 55 (22) | 20 (8) | 5 (2) |
| Anakinra | 250 | 95 (38) | 43 (17) | 15 (6) | ||
| Tocilizumab | Genovese34 | Placebo | 413 | 103 (25) | 37 (9) | 12 (3) |
| Tocilizumab | 803 | 488 (61) | 305 (38) | 169 (21) | ||
| Smolen35 | Placebo | 204 | 54 (26) | 22 (11) | 4 (2) | |
| Tocilizumab | 205 | 120 (59) | 90 (44) | 45 (22) | ||
| Maini36 | Placebo | 49 | 20 (41) | 14 (29) | 8 (16) | |
| Tocilizumab | 50 | 37 (74) | 27 (53) | 19 (37) | ||
| Kremer37 | Placebo | 393 | 106 (27) | — | — | |
| Tocilizumab | 398 | 223 (56) | — | — | ||
ACR: American College of Rheumatology.